임상 한눈에 보기

• 60건의 ClinicalTrials.gov 임상 기록
• Phase·Status 요약은 enrollment 상위 표본 기준입니다
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• Phase: Phase 3 · Phase 1, Phase 2 · Phase 1 · Phase 2
• Status: Completed · Recruiting · Not yet recruiting
• 주요 endpoint: To evaluate the Geometric mean RVNA Concentration (accessd by Rapid Fluorescent Foci Inhibition Test(RIFFIT)) for GR1801 recipients is non-inferior to the Geometric mean RVNA Concentration for HRIG recipients on Study Day 7. · To evaluate the percentage of subjects with RVNA concentration ≥ 0.5 IU/mL on Study Day 14 in GR1801 recipients is non-inferior to the percentage of subjects with RVNA concentration ≥ 0.5 IU/mL for HRIG. · To evaluate the rabies post-exposure protection rate for GR1801 recipients is non-inferior to the protection rate for HRIG recipients on Study Day 365. · To evaluate the rabies post-exposure morbidity of GR1801 compared to HRIG within 90 days and 365 days after administration. · To evaluate the rabies post-exposure mortality of GR1801 compared to HRIG within 90 days and 365 days after administration.
• 등록된 결과: ORR 11.1%
• 핵심: The primary objective of the study is to determine the maximum tolerated dose (MTD) of blinatumomab in combination with …

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.